Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6957235 | 0.87 | ALDH1A1 (0.46) | ALDH1A1KDM4EGPR119HPGDHRH3 | |
| SCHEMBL14317703 | 0.86 | GPR119 (0.47) | GPR119HPGDRECQLEPHX1USP2 | |
| SCHEMBL56379 | 0.85 | USP2 (0.53) | GPR119HPGDUSP2SMN1; SMN2 | |
| SCHEMBL4987189 | 0.82 | HPGD (0.51) | ALDH1A1KDM4ETP53TDP1GPR119 | |
| SCHEMBL20523370 | 0.82 | GPR119 (0.43) | ALDH1A1KDM4EGPR119HPGDHRH3 | |
| SCHEMBL994288 | 0.82 | HPGD (0.58) | ALDH1A1KDM4EGPR119HPGDRECQL | |
| SCHEMBL17128329 | 0.82 | HPGD (0.62) | KDM4EGPR119HPGDRECQLEPHX1 | |
| SCHEMBL65017 | 0.82 | HPGD (0.54) | ALDH1A1GPR119HPGDRECQLEPHX1 | |
| SCHEMBL1971010 | 0.82 | EPHX1 (0.55) | ALDH1A1GPR119HPGDRECQLEPHX1 | |
| SCHEMBL63877 | 0.81 | USP2 (0.53) | ALDH1A1KDM4EGPR119HPGDRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093239-B2 | Imidazopyridine kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100216779-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2010-08-26 | — | — | US | disclosed |
| WO-2010045451-A1 | PYRROLOPYRIMIDINE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-04-22 | — | — | WO | disclosed |
| EP-2162454-A1 | IMIDAZOPYRIDINE KINASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-03-17 | — | — | EP | disclosed |
| WO-2008150799-A1 | IMIDAZOPYRIDINE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | ABL1, MAP3K19, MAP3K5 | ALDH1A1 3410/4885KDM4E 790/4885TP53 831/4885 |
| US-20100216779-A1 | Imidazopyridine Kinase Inhibitors | ABL1, MAP3K19, MAP3K5 | ALDH1A1 3410/4885KDM4E 790/4885TP53 831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.